Results 1 to 10 of about 51,550 (240)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Cell Death and Disease, 2022
Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman, Yongkui Jing   +7 more
doaj   +2 more sources

Cytarabine-Induced Encephalitis

Journal of the Belgian Society of Radiology, 2021
Teaching Point: Central nervous system adverse effects of cytarabine treatment include aseptic meningitis, myelopathy, and more rarely, encephalopathy, seizures, and cerebellar dysfunction.
Christine Lenfant, Nathalie Greiner, Thierry Duprez   +2 more
doaj   +6 more sources

Optimization of Intra-Arterial Administration of Chemotherapeutic Agents for Glioblastoma in the F98-Fischer Glioma-Bearing Rat Model. [PDF]

Biomolecules
Glioblastoma (GBM) is a difficult disease to treat for different reasons, with the blood–brain barrier (BBB) preventing therapeutic drugs from reaching the tumor being one major hurdle.
Latulippe J, Roy LO, Gobeil F, Fortin D.
europepmc   +2 more sources

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

International Journal of Nanomedicine, 2019
Lawrence D Mayer, Paul Tardi, Arthur C LouieJazz Pharmaceuticals, Inc., Palo Alto, CA, USAAbstract: Combination regimens are a standard of care for many cancers.
Mayer LD, Tardi P, Louie AC
doaj   +2 more sources

AML beyond the boundaries of daunomycin and cytarabine [PDF]

Blood, 2003
Since the introduction of the anthracyclins and cytarabine some decades ago, there has been little progress in remission induction therapy of acute myeloid leukemia (AML). Genetic lesions in AML uncovered by molecular analysis provide opportunities for therapeutic targeting.
Bob Löwenberg
openalex   +4 more sources

Cytarabine syndrome revisited [PDF]

British Journal of Haematology, 2003
Wee Joo Chng
openalex   +4 more sources

Enhanced Antitumor Efficacy of Cytarabine and Idarubicin in Acute Myeloid Leukemia Using Liposomal Formulation: In Vitro and In Vivo Studies. [PDF]

Pharmaceutics
Background: Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with the recommend therapy of combination of cytarabine and idarubicin in the induction phase.
Zhu C, Liu Y, Ji X, Si Y, Tao X, Zhang X, Yin L.   +6 more
europepmc   +2 more sources

Effect of Rutin on Cytarabine-Associated Pulmonary Oedema and Oxidative Stress in Rats [PDF]

Anais da Academia Brasileira de Ciências, 2020
Cytarabine is effectively used in the treatment of adult acute leukemia, but it has a dose-limiting side effect of fatal pulmonary oedema because it increases the vascular permeability of the alveolar capillaries.
ASLI O. BILGIN, RENAD MAMMADOV, BAHADIR SULEYMAN, EDHEM UNVER, FATIH OZCICEK, MEHMET SOYTURK, FERDA K. CIMEN, NEZAHAT KURT, HALIS SULEYMAN   +8 more
doaj   +1 more source

Interaction of Lipophilic Cytarabine Derivatives with Biomembrane Model at the Air/Water Interface

Membranes, 2022
Cell membrane models are useful for obtaining molecular-level information on the interaction of biologically active molecules whose activity is believed to depend also on their effects on the membrane.
Jhon Fernando Berrio Escobar, Cristiano Giordani, Stefano Russo, Francesco Castelli, Maria Grazia Sarpietro   +4 more
doaj   +1 more source

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Blood Advances, 2022
Key Points Adding idasanutlin to cytarabine to treat R/R AML improved overall remission rate (CR+CRi+CRp) but not overall survival (138).
M. Konopleva, C. Röllig, J. Cavenagh, D. Deeren, L. Girshova, J. Krauter, G. Martinelli, P. Montesinos, J. Schäfer, O. Ottmann, M. Petrini, A. Pigneux, A. Rambaldi, C. Récher, R. Rodríguez-Veiga, D. Taussig, N. Vey, S. Yoon, M. Ott, S. Muehlbauer, Benjamin M. Beckermann, O. Catalani, M. Genevray, K. Mundt, C. Jamois, P. Fenaux, A. Wei   +26 more
semanticscholar   +1 more source